Klotho Neurosciences (NASDAQ:KLTO) (NASDAQ: KLTO) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel therapies that target the Klotho protein, a key regulator of aging and tissue repair. By focusing on small‐molecule modulators that upregulate endogenous α-Klotho expression, the company aims to address a range of age-related and neurodegenerative diseases, including Alzheimer’s disease, chronic kidney disease and muscle wasting disorders. Its proprietary platform combines high-throughput screening with advanced medicinal chemistry to identify candidates with favorable drug‐like properties and central nervous system penetration.
The company’s lead asset, KNT-127, is in IND-enabling studies and is designed to enhance Klotho levels in the brain and peripheral tissues. Preclinical data have shown that KNT-127 promotes synaptic resilience, reduces neuroinflammation and supports cognitive function in animal models of neurodegeneration. In parallel, Klotho Neurosciences is advancing additional discovery programs focused on small molecules that act through complementary pathways, as well as exploring combination strategies to maximize therapeutic benefit. Its R&D efforts are supported by collaborations with academic research centers and contract research organizations across North America and Europe.
Founded in 2020 and headquartered in San Diego, California, Klotho Neurosciences operates research laboratories in key biotech hubs and maintains strategic partnerships with leading translational research institutions. The company holds a robust intellectual property portfolio, including multiple issued patents covering small‐molecule Klotho activators and methods for their use in treating age-related pathologies. By leveraging its deep expertise in protein biology and drug discovery, Klotho Neurosciences aims to advance its pipeline into clinical trials and bring first-in-class therapies to patients with high unmet medical needs.
Klotho Neurosciences is led by a team of seasoned biopharmaceutical executives and scientists with extensive experience in neurology, nephrology and clinical development. The leadership team is supported by a scientific advisory board composed of prominent researchers in aging and regenerative medicine. Together, they are committed to translating groundbreaking science into meaningful therapies that may slow, halt or reverse the progression of debilitating diseases associated with aging.
